Syntheses, reactivity, and biological applications of coumarins
This comprehensive review, covering 2021–2023, explores the multifaceted chemical and
pharmacological potential of coumarins, emphasizing their significance as versatile natural …
pharmacological potential of coumarins, emphasizing their significance as versatile natural …
Benzopyrone, a privileged scaffold in drug discovery: An overview of FDA‐approved drugs and clinical candidates
V Sharma, A Sharma, BN Wadje… - Medicinal Research …, 2024 - Wiley Online Library
Natural products have always served as an important source of drugs for treating various
diseases. Among various privileged natural product scaffolds, the benzopyrone class of …
diseases. Among various privileged natural product scaffolds, the benzopyrone class of …
Pharmacodynamic drug-drug interactions and bleeding outcomes in patients with atrial fibrillation using non-vitamin K antagonist Oral anticoagulants: a Nationwide …
M Grymonprez, A Capiau, S Steurbaut… - … Drugs and Therapy, 2023 - Springer
Purpose Pharmacodynamic drug-drug interactions (PD DDIs) may influence the safety of
non-vitamin K antagonist oral anticoagulants (NOACs), but the extent to which PD DDIs …
non-vitamin K antagonist oral anticoagulants (NOACs), but the extent to which PD DDIs …
Oral anticoagulation in heart failure complicated by atrial fibrillation: A nationwide routine data study
M Moeckel, S Pudasaini, HT Baberg… - International Journal of …, 2024 - Elsevier
Background This nationwide routine data analysis evaluates if oral anticoagulant (OAC) use
in patients with heart failure (HF) and atrial fibrillation (AF) leads to a lower mortality and …
in patients with heart failure (HF) and atrial fibrillation (AF) leads to a lower mortality and …
Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin‐K antagonists: A retrospective German claims data …
C Engelbertz, U Marschall, J Feld… - Journal of Internal …, 2024 - Wiley Online Library
Abstract Background Vitamin‐K antagonists (VKAs) have widely been replaced by non‐VKA
oral anticoagulants (NOACs). This includes Austria, Germany and Switzerland, where as …
oral anticoagulants (NOACs). This includes Austria, Germany and Switzerland, where as …
Pharmacokinetics of phenprocoumon in emergency situations–results of the prospective observational RADOA-registry (reversal agent use in patients treated with …
E Lindhoff-Last, I Birschmann, AJ Bidenharn, J Kuhn… - Pharmaceuticals, 2022 - mdpi.com
Background: Phenprocoumon has been used as an oral anticoagulant in patients with
thromboembolic disease for more than 40 years. So far its pharmacokinetics have not been …
thromboembolic disease for more than 40 years. So far its pharmacokinetics have not been …
Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
C Stöllberger, B Schneider… - Expert Review of Clinical …, 2023 - Taylor & Francis
Introduction In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the
vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial …
vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial …
Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants
A Abdrakhmanov, A Shaimerdinova… - Therapeutic …, 2024 - journals.sagepub.com
Atrial fibrillation (AF) accounts for 40% of all cardiac arrhythmias and is associated with a
high risk of stroke and systemic thromboembolic complications. Dabigatran, rivaroxaban …
high risk of stroke and systemic thromboembolic complications. Dabigatran, rivaroxaban …
[HTML][HTML] Thrombotic and Hemorrhagic Complications Following Left Ventricular Assist Device Placement: An Emphasis on Gastrointestinal Bleeding, Stroke, and …
J Phan, K Elgendi, M Javeed, JM Aranda, MM Ahmed… - Cureus, 2023 - ncbi.nlm.nih.gov
The left ventricular assist device (LVAD) is a mechanical circulatory support device that
supports the heart failure patient as a bridge to transplant (BTT) or as a destination therapy …
supports the heart failure patient as a bridge to transplant (BTT) or as a destination therapy …
Oral anticoagulation in heart failure complicated by atrial fibrillation: Outcomes in routine data
M Möckel, S Pudasaini, HT Baberg, B Levenson… - medRxiv, 2023 - medrxiv.org
Background Aim of this study was to test if oral anticoagulant (OAC) use in patients with
heart failure (HF), accompanied by atrial fibrillation (AF), leads to a favorable outcome …
heart failure (HF), accompanied by atrial fibrillation (AF), leads to a favorable outcome …